Economic Burden of Psoriasis in the United States

Brezinski, Elizabeth A.; Dhillon, Jaskaran S.; Armstrong, April W.

doi:10.1001/jamadermatol.2014.3593

Cited by 218 publications

(206 citation statements)

References 35 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…Twenty of 26 serious infections surveyed had higher mean costs of hospitalization and 23 of 26 had higher LOS than that for patients with psoriasis without serious infections. On a national level, psoriasis presents a substantial economic burden 19 and mitigation of infectious complications would dramatically reduce cost. Although we demonstrate that serious infections are on the rise in inpatients with psoriasis, these trends were not only observed in patients with psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Serious infections in hospitalized patients with psoriasis in the United States

Hsu

Gordon

Silverberg

2016

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Serious infections in hospitalized patients with psoriasis in the United States

Hsu

Gordon

Silverberg

2016

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…These results were not surprising because psoriatic disease is associated with a substantial economic burden, with costs around $135 billion annually in the United States alone 37 . Although data from the NPF indicate that 91% of patients with psoriatic disease have insurance coverage, out-of-pocket costs ranged anywhere from $2500 to $8000 in patients with psoriasis and PsA, with indirect costs accounting for 52% to 72% of total PsA costs 37,38,39,40 . Not surprisingly, increased costs are contributing to undertreatment of patients with psoriatic disease 41 .…”

Section: Rheumatologymentioning

confidence: 96%

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi

Doogan²,

Heid³

et al. 2018

J Rheumatol

View full text Add to dashboard Cite

Objective.To evaluate the types of experiences and treatment access challenges of patients with psoriatic arthritis (PsA) using self-reported online narratives.Methods.English-language patient narratives reported between January 2010 and May 2016 were collected from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums, mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment. Using natural language processing and manual curation, patient-reported experiences were categorized into 6 high-level concepts of functional impairment [social, physical, emotional, cognitive, role activity (SPEC-R), and general] and 6 categories to determine barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence, doctor guidance). The SPEC-R categorization was also applied to 3 validated PsA patient-reported outcome (PRO) instruments to evaluate their capacity to collect lower-level subconcepts extracted from patient narratives.Results.Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. Cognitive impairments and disease burden on family and parenting were not recorded by PsA PRO instruments. The most commonly cited barriers to treatment were coverage ineligibility (51.6%) and high out-of-pocket expenses (31.7%).Conclusion.Patients often discussed physical and emotional implications of PsA in online platforms; some commonly used PRO instruments in PsA may not identify cognitive issues or parenting/family burden. Nearly one-third of patients with PsA reported access barriers to treatment.

show abstract

“…Biologic monoclonal antibody therapy is the cornerstone of treatment of inflammatory diseases including inflammatory bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis (UC)), rheumatoid arthritis (RA), and psoriasis (PsA) Ordas et al, 2012;Ramiro et al, 2016;Singh et al, 2016) which affect over 10 million individuals in the United States (Brezinski et al, 2015;Cross et al, 2014;Molodecky et al, 2012). In each of these diseases, biologic therapy reduces disease-related morbidity Ordas et al, 2012;Ramiro et al, 2016;Singh et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiome Function Predicts Response to Anti-Integrin Biologic Therapy in Inflammatory Bowel Diseases

et al. 2017

View full text Add to dashboard Cite

The gut microbiome plays a central role in inflammatory bowel diseases (IBD) pathogenesis and propagation. To determine if the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and 54 after therapy initiation were assessed. Community α-diversity was significantly higher, and Roseburia inulinivorans and a Burkholderiales species were more abundant at baseline among CD patients achieving week 14 remission. Several significant associations were identified with microbial function; 13 pathways including branched chain amino acid synthesis were significantly enriched in baseline samples from CD patients achieving remission. A neural network algorithm, vedoNet, incorporating microbiome and clinical data, and provided highest classifying power for clinical remission. We hypothesize that the trajectory of early microbiome changes may be a marker of response to IBD treatment.

show abstract

Economic Burden of Psoriasis in the United States

Abstract: The economic burden of psoriasis is substantial and significant in the United States.

Cited by 218 publications

References 35 publications

Serious infections in hospitalized patients with psoriasis in the United States

Serious infections in hospitalized patients with psoriasis in the United States

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Gut Microbiome Function Predicts Response to Anti-Integrin Biologic Therapy in Inflammatory Bowel Diseases

Contact Info

Product

Resources

About